OVARIAN CANCER and US: liposomal encapsulated doxorubicin

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label liposomal encapsulated doxorubicin. Show all posts
Showing posts with label liposomal encapsulated doxorubicin. Show all posts

Friday, April 23, 2010

Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Collaboration Database Systematic Review



CONCLUSIONS:
We are not able to favour either epirubicin or doxorubicin when given with the same dose. Based on the currently available evidence on heart failure, we conclude that in adults with a solid tumour liposomal-encapsulated doxorubicin should be favoured over doxorubicin. For both epirubicin versus doxorubicin and liposomal-encapsulated doxorubicin versus conventional doxorubicin no conclusions can be made about the effects of treatment in children treated with anthracyclines and also not in patients diagnosed with leukaemia. More research is needed. For other combinations of anthracycline derivates not enough evidence was available to make definitive conclusions about the occurrence of cardiotoxicity in patients treated with anthracyclines.

CCardiology
Probably an important review but it would have been more helpful for the general practitioner if the authors also reviewed or at least discussed the role of ACE-Inhibitors given before anthracycline treatment in these patients.
ommentary (1) at present: